1582 related articles for article (PubMed ID: 28549077)
1. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
Fereshtehnejad SM; Zeighami Y; Dagher A; Postuma RB
Brain; 2017 Jul; 140(7):1959-1976. PubMed ID: 28549077
[TBL] [Abstract][Full Text] [Related]
2. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes.
Fereshtehnejad SM; Romenets SR; Anang JB; Latreille V; Gagnon JF; Postuma RB
JAMA Neurol; 2015 Aug; 72(8):863-73. PubMed ID: 26076039
[TBL] [Abstract][Full Text] [Related]
3. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
Fullard ME; Tran B; Xie SX; Toledo JB; Scordia C; Linder C; Purri R; Weintraub D; Duda JE; Chahine LM; Morley JF
Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
[TBL] [Abstract][Full Text] [Related]
4. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
[TBL] [Abstract][Full Text] [Related]
6. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
Wilson EN; Swarovski MS; Linortner P; Shahid M; Zuckerman AJ; Wang Q; Channappa D; Minhas PS; Mhatre SD; Plowey ED; Quinn JF; Zabetian CP; Tian L; Longo FM; Cholerton B; Montine TJ; Poston KL; Andreasson KI
Brain; 2020 Mar; 143(3):932-943. PubMed ID: 32065223
[TBL] [Abstract][Full Text] [Related]
7. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
Skogseth RE; Bronnick K; Pereira JB; Mollenhauer B; Weintraub D; Fladby T; Aarsland D
J Parkinsons Dis; 2015; 5(4):783-92. PubMed ID: 26599300
[TBL] [Abstract][Full Text] [Related]
8. Predicting severity and prognosis in Parkinson's disease from brain microstructure and connectivity.
Abbasi N; Fereshtehnejad SM; Zeighami Y; Larcher KM; Postuma RB; Dagher A
Neuroimage Clin; 2020; 25():102111. PubMed ID: 31855654
[TBL] [Abstract][Full Text] [Related]
9. Data-Driven Subtyping of Parkinson's Disease Using Longitudinal Clinical Records: A Cohort Study.
Zhang X; Chou J; Liang J; Xiao C; Zhao Y; Sarva H; Henchcliffe C; Wang F
Sci Rep; 2019 Jan; 9(1):797. PubMed ID: 30692568
[TBL] [Abstract][Full Text] [Related]
10. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease.
Pagano G; De Micco R; Yousaf T; Wilson H; Chandra A; Politis M
Neurology; 2018 Sep; 91(10):e894-e905. PubMed ID: 30089615
[TBL] [Abstract][Full Text] [Related]
11. CSF biomarkers and clinical progression of Parkinson disease.
Hall S; Surova Y; Öhrfelt A; Zetterberg H; Lindqvist D; Hansson O
Neurology; 2015 Jan; 84(1):57-63. PubMed ID: 25411441
[TBL] [Abstract][Full Text] [Related]
12. CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.
Terrelonge M; Marder KS; Weintraub D; Alcalay RN
J Mol Neurosci; 2016 Jan; 58(1):88-92. PubMed ID: 26330275
[TBL] [Abstract][Full Text] [Related]
13. Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson's disease.
Modreanu R; Cerquera SC; Martí MJ; Ríos J; Sánchez-Gómez A; Cámara A; Fernández M; Compta Y
J Neurol Sci; 2017 Feb; 373():223-229. PubMed ID: 28131192
[TBL] [Abstract][Full Text] [Related]
14. In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease.
Ray NJ; Bradburn S; Murgatroyd C; Toseeb U; Mir P; Kountouriotis GK; Teipel SJ; Grothe MJ
Brain; 2018 Jan; 141(1):165-176. PubMed ID: 29228203
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
16. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
17. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
[TBL] [Abstract][Full Text] [Related]
18. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
[TBL] [Abstract][Full Text] [Related]
19. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease.
Postuma RB; Gagnon JF; Vendette M; Montplaisir JY
Brain; 2009 Dec; 132(Pt 12):3298-307. PubMed ID: 19843648
[TBL] [Abstract][Full Text] [Related]
20. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
Liu C; Cholerton B; Shi M; Ginghina C; Cain KC; Auinger P; ; Zhang J
Parkinsonism Relat Disord; 2015 Mar; 21(3):271-6. PubMed ID: 25596881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]